Hematology: Thalidomide maintenance in multiple myeloma

Nat Rev Clin Oncol. 2009 Oct;6(10):565-6. doi: 10.1038/nrclinonc.2009.131.
No abstract available

Publication types

  • News

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Chromosomes, Human, Pair 13
  • Clinical Trials, Phase III as Topic
  • Dexamethasone / administration & dosage
  • Disease Progression
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Drug Administration Schedule
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / mortality
  • Multiple Myeloma / pathology
  • Randomized Controlled Trials as Topic
  • Stem Cell Transplantation*
  • Survival Analysis
  • Thalidomide / therapeutic use*
  • Time Factors
  • Transplantation, Autologous
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Immunosuppressive Agents
  • Thalidomide
  • Vincristine
  • Dexamethasone
  • Doxorubicin